Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025142 · ClinicalTrials.gov registry record · Phase 2
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00025142: Completed Phase 2 study, sponsored by Stanford University.
NCT00025142 is a Phase 2 study that has completed, run by Stanford University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025142, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with gefitinib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gefitinib and oxaliplatin combined with leucovorin and fluorouracil in treating patients who have advanced solid tumors or colorectal cancer.
Interventions
- DRUG FOLFOX regimen
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025142
The ClinicalTrials.gov registry entry for NCT00025142 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which FOLFOX regimen is the first listed.
NCT00025142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025142 about?
NCT00025142 is a clinical study titled "Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer". RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with gefitinib may kill more tumo...
What is the current status of trial NCT00025142?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00025142?
The interventions under investigation include: FOLFOX regimen (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00025142?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.